|D045169||Severe Acute Respiratory Syndrome NIH||0.10|
|D003141||Communicable Diseases NIH||0.08|
|D018352||Coronavirus Infections NIH||0.08|
There are 2 clinical trials
The main purpose of this study is to evaluate the activity of low dose oral selinexor (KPT-330) and to evaluate the clinical recovery, the viral load, length of hospitalization and the rate of morbidity and mortality in patients with severe COVID-19 compared to placebo.
Description: The ViVi or Vienna Vaccine Safety Initiative Disease Severity Score ranges from 0 to 22 with the disease severity indicated by increasing score. It is used to score disease severity and risk in patients with influenza-like illness and/or other forms of acute respiratory infections (e.g. RSV, adenovirus metapneumovirus, rhinovirus and other respiratory viral pathogens), including in infants and children. The Investigator will ask yes/no questions to the patient, and the mobile application will automatically calculate the score.Measure: Change in Vienna Vaccine Safety Initiative (ViVI) Disease Severity Score Time: Up to Day 28
The main purpose of this study is to evaluate the activity, safety and reduction in mortality of two regimens of low dose selinexor (KPT-330) in patients with moderate or severe COVID-19.